Fusion Pharmaceuticals (FUSN) said Friday it received a final court order approving the acquisition of the company by a wholly-owned subsidiary of AstraZeneca (AZN).
Under the deal, Fusion shareholders will receive $21 per share in cash upfront plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of $3.00 a share, the firm said.
The company expects to close the transaction in Q2 this year.
Price: 21.56, Change: +0.04, Percent Change: +0.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments